All Updates

All Updates

icon
Filter
Partnerships
Reveal Genomics to evaluate HER2DX genomic test with Dana-Farber Cancer Institute
Precision Medicine
Jun 18, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 18, 2024

Reveal Genomics to evaluate HER2DX genomic test with Dana-Farber Cancer Institute

Partnerships

  • Reveal Genomics has announced the start of a prospective study in collaboration with the Dana-Farber Cancer Institute to evaluate the turnaround time of the HER2DX genomic test for its feasibility in clinical practice in the US. The HER2DX test results are currently generated and managed in Spain.

  • The HER2DX is a standardized 27-gene expression test for early-stage HER2+ breast cancer patients. It integrates clinical information with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and HER2 17q12-21 chromosomal amplicon expression. 

  • According to the company, the test predicts the risk of relapse score, response to anti-HER2-based treatment before surgery (pCR likelihood score), and the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low, and HER2+ breast cancer (ERBB2 score).

  • Reveal Genomics is a biotechnology company headquartered in Spain focused on precision oncology through genomic diagnostics. It aims to improve cancer treatment by developing diagnostic tests that leverage comprehensive genomic and clinical data. Its flagship product, HER2DX, is a genomic test specifically designed for HER2-positive breast cancer, providing prognostic and predictive insights to tailor treatment strategies​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.